LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Advanced Medical Equipment & Technology

Delayed OTC Markets 12:42:49 2024-04-18 pm EDT 5-day change 1st Jan Change
0.018 USD -31.03% Intraday chart for LumiraDx Limited +50.00% -71.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Midday Decliners MT
LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index CI
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data MT
Top Premarket Decliners MT
Roche to buy part of LumiraDx diagnostics platform for $295 million RE
LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche DJ
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech MT
Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday MT
Top Premarket Decliners MT
LumiraDx Limited Announces Resignation of Lu Huang from the Board of Directors CI
LumiraDx Limited Announces Board Appointments CI
LumiraDx Limited Appoints Veronique Ameye as the Company?s Chief Executive Officer and General Counsel, Effective as of November 1, 2023 CI
LumiraDx Limited Announces Board Resignations CI
LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer CI
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth MT
LumiraDx to Partner With AstraZeneca, Everton Charity Arm For Heart And Lung Screening Hub MT
Investors Await Economic, Inflation Data as US Futures Trend Lower in Monday's Premarket MT
Top Premarket Gainers MT
LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors CI
LumiraDx Limited(NasdaqGM:LMDX) dropped from S&P Global BMI Index CI
Raymond James Adjusts LumiraDx Price Target to $0.80 From $1, Maintains Outperform Rating MT
Transcript : LumiraDx Limited, Q2 2023 Earnings Call, Aug 24, 2023
Earnings Flash (LMDX) LUMIRADX Reports Q2 Revenue $21M, vs. Street Est of $21.5M MT
LumiraDx Limited Announces Executive Changes CI
LumiraDx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart LumiraDx Limited
More charts
LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The Company offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. It also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.
More about the company
  1. Stock Market
  2. Equities
  3. LMDXF Stock
  4. News LumiraDx Limited
  5. LumiraDx : Health Care Stocks Advance Pre-Bell Wednesday